Related Experiment Video
Updated: May 30, 2026
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
[Treatment with rituximab for thrombocytopenia due to systemic lupus erythematosus]
Rosa Elena Calderón Saldierna1, María Azucena Ramos Sánchez, Yadhira Mejía Holguín
1Unidad Médica de Alta Especialidad N.(o) 25 del IMSS, Monterrey, México.
Unlabelled:
Some patients with thrombocytopenia due SLE fail to respond to conventional therapies. Rituximab has been reported to be an alternative for patient treatment.
Objective:
To evaluate the response of thrombocytopenia due to Systemic Lupus Erythematosus to the use of Rituximab and patient relapse time at our hospital.
Patients And Methods:
We analyzed patients with SLE than received a 2 gram rituximab treatment for thrombocytopenia. We analyzed the rate of patients that achieved complete remission (CR), defined as a platelet count over 100mil/mm(3), partial remission (PR) described as platelets within 50-100mil/mm(3) and no response (NR) if platelets remained unchanged and the time the remission was sustained.
Results:
16 treatments were applied to 13 patients, aged 28±9 years of age and SLE mean duration time of 68±44 months with a mean platelet count of 38±29mil. In 14 treatments (87%) remission was achieved after 5±2 weeks where 2 patients (12.5%) were non respondent. One of them died due to a massive hemorrhage. The mean response time without relapse was 15.6±6 months. Follow up of three patients was not possible and 3 other died due to infections.
Conclusions:
Rituximab is an alternative for treatment of thrombocytopenia due to Systemic Lupus Erythematosus.
Related Concept Videos
01:21Rheumatic Heart Disease III: Medical Management
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents